Author:
Neelapu Sattva S.,Tummala Sudhakar,Kebriaei Partow,Wierda William,Locke Frederick L.,Lin Yi,Jain Nitin,Daver Naval,Gulbis Alison M.,Adkins Sherry,Rezvani Katayoun,Hwu Patrick,Shpall Elizabeth J.
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Teachey, D. T. et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat. Rev. Clin. Oncol. https://doi.org/10.1038/nrclinonc.2018.19 (2018).
2. Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47–62 (2018).
3. Schuster, S. J. et al. Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 130, 577 (2017).
4. Abramson, J. et al. High durable CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort. Blood 130, 581 (2017).
5. Grupp, S. A. et al. Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood 128, 221 (2016).
Cited by
145 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献